Mild cognitive impairment (MCI) has been defined as the stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Its clinical characteristics represent the earliest features of many forms of dementia. Specifically, many studies have reported amnestic MCI (aMCI) as a risk factor for Alzheimer’s disease, but to date there’s still a need for establishing specific, reliable, pre-symptomatic and non-invasive biomarkers associated to the progression of aMCI to AD. In this study we investigated CSF and structural MRI biomarkers for the classification of high and low risk of dementia conversion in aMCI.
This abstract and the presentation materials are available to members only; a login is required.